FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Boehringer Ingelheim Pharmaceuticals Synjardy XR Tablets Recall

Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets…

Boehringer Ingelheim Pharmaceuticals, Inc. · Ridgefield, CT

Risk level
Class II
Reported by FDA
Jul 8, 2026
Recall ID
D-0657-2026
Check your lot numberHow we source this data

Summary

Boehringer Ingelheim Pharmaceuticals recalled Synjardy XR Tablets starting Jun 12, 2026. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0657-2026 on Jul 8, 2026. Reason: CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product. Status: Ongoing.

Why it was recalled

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Product description

Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets), 12.5/1000 mg, 60 Tablets per Bottle, Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA. NDC: 00597-0300-45

Lot numbers, UPCs & expiration codes

Lot 3244413; Exp. 12/31/2028

Where it was sold

OH

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0657-2026
Classification
Class II
Status
Ongoing
Recall initiated
Jun 12, 2026
FDA report date
Jul 8, 2026
Quantity
560 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Boehringer Ingelheim Pharmaceuticals, Inc.

Original FDA data

Every field from FDA enforcement report D-0657-2026, exactly as published.

Show all FDA fields
City
Ridgefield
State
CT
Status
Ongoing
Country
United States
Event ID
99233
Address
900 Ridgebury Rd
Code information
Lot 3244413; Exp. 12/31/2028
Postal code
06877-1058
Report date
Jul 8, 2026
Product type
Drugs
Recall number
D-0657-2026
Classification
Class II
Recalling firm
Boehringer Ingelheim Pharmaceuticals, Inc.
Product quantity
560 bottles
Reason for recall
CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets), 12.5/1000 mg, 60 Tablets per Bottle, Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA. NDC: 00597-0300-45
Distribution pattern
OH
Recall initiation date
Jun 12, 2026
Initial firm notification
Letter
Center classification date
Jun 30, 2026

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0657-2026, published Jul 8, 2026. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls